Fact CheckerSign in

NCT06439745Completed

More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated

More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated

Source: ClinicalTrials.gov · Last updated 2 Sept 2025

Brief summary (registry, in English)

In absence of nodal metastases or aggressive features, thyroid lobectomy (TL) should be preferred over total thyroidectomy (TT) for small unifocal papillary thyroid carcinoma (PTC). However, occult, despite non-microscopic (\>2 mm), nodal metastases may be present in clinically node-negative (cN0) PTCs. Among 4216 thyroidectomies for malignancy (2014-2023), 110 (2.6%) TL plus ipsilateral central neck dissection (I-CND) were scheduled for unifocal cT1b/small cT2 (\<3 cm) cN0 PTCs. Nodes frozen section examination (FSE) was performed: when positive, completion thyroidectomy (CT) was accomplished during the same procedure. In presence of aggressive pathologic features, CT was suggested within 6 months from index operation.

Status (registry)
Completed
Study type
Observational
Enrollment
314 (actual)
First submitted
7 Mar 2024
Start date
Sept 2014
Primary completion date
Sept 2023
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT number
NCT06439745

What you commit to

  • Study type: Observational
  • Participants enrolled: 314
  • From Sept 2014 to the primary completion date, Sept 2023
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • prior head or neck irradiation

Other illness

  • family history of thyroid carcinoma

Age

  • age \< 18

Other

  • clinical evidence of multifocality
  • extrathyroidal extension or LN metastases
  • follow-up \< 6 months.

Who the study is looking for

  • age\>18
  • classic papillary carcinoma and variants
  • clinically unifocal and intrathyroidal PTC
  • clinical tumor size \>1 cm and ≤3 cm
  • no clinical evidence of LN involvement

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.